RxDoctor Payments DataLook up a doctor →

Leonardo Kapural, MD

Pain Medicine · Winston Salem, NCNPI 1447355029

Payments from drug & device makers

$4,061,463in general payments, 2019–2025

Across 1,091 payments — averaging $3722.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$1.3M
  • Nalu Medical, Inc.$900K
  • Avanos Medical$888K
  • SPR Therapeutics, Inc$297K
  • Saluda Medical Americas, Inc.$295K
  • Eli Lilly$110K
  • plus $239K from 39 others
$206,618in research payments, 2019–2025

Across 1,265 payments — averaging $163.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotronik Inc.$159K
  • Nevro Corp.$45K
  • Saluda Medical Americas, Inc.$2K
  • Eli Lilly$1K

What the payments were for

  • Consulting fees$178,03834%
  • Speaking & faculty fees$254,43749%
  • Travel & lodging$45,2959%
  • Food & beverage$28,8846%
  • Education$4,5321%
  • Ownership interest$1,7770%
  • Other$10,5182%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,061,463 in reported general payments places this provider in the 95th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$354,210
Medicare patients
341
Services billed
3,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl74$53,501
Xtampza ErOxycodone Myristate25$21,641
Buprenorphine41$12,646
Lidocaine21$3,191
Gabapentin112$2,799
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen66$2,066
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen75$2,036
Naloxone Hcl26$1,520
Pregabalin34$1,485
Tramadol Hcl111$1,479
Cephalexin89$983
Oxcarbazepine11$492
Hydromorphone Hcl28$429
Oxycodone Hcl29$419
Tizanidine Hcl13$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$340$75,14299 claims
Hikma Pharmaceuticals USABuprenorphine$25$12,64641 claims
Dr.reddy's Laboratories,inc.Pregabalin$898$1,48534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →